Press Release

HEXAGON NUTRITION LIMITED ·Nutritionally Yours... Ref: HNL/SEC/2026-27 /18 Date: 13.08.2026 BSE Limited National Stock Exchange of India Limited Corporate Relationship Department, Exchange Plaza, C-1, Block G, Bandra-Kurla Phiroze Jeejeebhoy Towers, Complex, Bandra (E), Mumbai- 400 051. Dalal Street, Mumbai -- 400001. NSE Symbol: HEXAGON Scrip Code: 544785 Re: HEXAGON NUTRITION LIMITED - ISIN: INE0JUI01012 Subject: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")-Media Release Dear Sir/Madam, Pursuant to the provisions of Regulation 30 of the Listing Regulations, please find enclosed herewith the Earnings Release for the Financial Results for the quarter ended June 30, 2026. The disclosure will also be available on the Company's website at www.hexagonnutrition.com This is for your information and records. Thanking you, For and on behalf of Hexagon Nutrition Limited Ms. Vedanti Vartak Designation: Company Secretary & Compliance Officer ICSI Membership Number: A41580 Encl: As above CIN:- L24110MH1993PLC072189 Nashik Plant : Registered Office : Plot No. 92 & Plot No. 447, Unandanagar, Lakhamapur, 404 Global Chamber, Adarsh Nagar, Link Road, Dindori, Nasik - 422 202, Maharashtra, India Andheri (W), Mumbai, Maharashtra - 400053, India Tel. No.: +91-22-62136710/711 Chennai Plant : Website : www.hexagonnutrition.com Plot No. B11 Phase - 1 MEPZ-SEZ, Tambaram, Email ID: enquiry@hexagonnutrition.com Chennai - 600 045, Tamil Nadu, India Tel. No.: +91-44-22625252 HNL-081 Email ID: infochennai@hexagonnutrition.com Earnings Release Q1 FY27 Earnings Release Hexagon Nutrition reports Q1 FY27 revenue of ₹104.3 crore, up 43.2% YoY; PAT grows 25.1% to ₹8.1 crore Company's first quarterly results as a listed entity following its June 2026 IPO; EBITDA up 17.3% YoY to ₹11.8 crore Mumbai, August 12, 2026: Hexagon Nutri(cid:415)on Limited ("Hexagon" or "the Company"), a leading global nutri(cid:415)on company engaged in the manufacturing and marke(cid:415)ng of micronutrient premixes, therapeu(cid:415)c nutri(cid:415)on products, clinical nutri(cid:415)on, food for(cid:415)fica(cid:415)on solu(cid:415)ons and consumer nutri(cid:415)on products today announced its financial results for the first quarter ended June 30, 2026 (Q1 FY27) — its first quarterly disclosure since lis(cid:415)ng on the BSE and NSE in June 2026. The company reported revenue from opera(cid:415)ons of ₹104.3 crore in Q1 FY27, up 43.2% from ₹72.9 crore in Q1 FY26. EBITDA rose 17.3% year-on-year to ₹11.8 crore, with an EBITDA margin of 11.3%, compared to 13.8% in the corresponding quarter last year. Profit a(cid:332)er tax grew 25.1% YoY to ₹8.1 crore, with a PAT margin of 7.7% against 8.9% in Q1 FY26 Key Consolidated Financial Summary (in cr’s) Particulars (₹ Q1 FY27 Q1 FY26 YoY FY26 FY25 YoY Crore) Revenue from 104.3 72.9 43.2% 382.6 324.9 17.8% Operations EBITDA 11.8 10.1 17.3% 52.9 40.1 31.9% EBITDA Margin 11.3% 13.8% (250 bps) 13.8% 12.3% +150 bps Profit After Tax 8.1 6.5 25.1% 37.9 24.3 56.1% (PAT) PAT Margin 7.7% 8.9% (120 bps) 9.9% 7.5% +240 bps Basic EPS (₹) 0.67 0.58 15.5% 3.43 1.75 96.0% Diluted EPS (₹) 0.66 0.53 24.5% 3.09 1.57 96.8% EBITDA has been computed as Profit before Tax + Finance Cost + Deprecia(cid:415)on & Amor(cid:415)sa(cid:415)on less Other Income. Financial Highlights – Q1 FY27  Revenue from Opera(cid:415)ons stood at Rs. 104.3 crore, registering a 43.2% YoY growth compared with Rs. 72.9 crore in Q1 FY26.  Gross Profit stood at Rs. 45.8 crore, up 34.1% YoY from Rs. 34.1 crore. Earnings Release  EBITDA stood at Rs. 11.8 crore, registering 17.3% YoY growth compared with Rs. 10.1 crore.  EBITDA margin stood at 11.3%.  Profit Before Tax stood at Rs. 10.6 crore, up 25.1% YoY.  Profit A(cid:332)er Tax stood at Rs. 8.1 crore, registering 25.1% YoY growth compared with Rs. 6.5 crore.  PAT margin stood at 7.7%. Commen(cid:415)ng on the performance, Mr. Arun Kelkar, Chairman & Execu(cid:415)ve Director, "We have started FY27 with strong revenue momentum, with consolidated revenue from opera(cid:415)ons growing 43.2% year-on-year to Rs. 104.3 crore. This performance reflects the con(cid:415)nued demand for our nutri(cid:415)on solu(cid:415)ons and the progress we are making across our domes(cid:415)c and interna(cid:415)onal markets. Our focus remains on building a diversified and scalable nutri(cid:415)on pla(cid:414)orm across Micronutrient Premixes, Clinical Nutri(cid:415)on and Therapeu(cid:415)c Nutri(cid:415)on. We con(cid:415)nue to see significant opportuni(cid:415)es in interna(cid:415)onal markets, supported by our presence across more than 70 countries, as well as in the growing clinical and func(cid:415)onal nutri(cid:415)on segments. As we enter this new phase as a listed company, our priori(cid:415)es remain unchanged — sustainable revenue growth, stronger interna(cid:415)onal presence, innova(cid:415)on-led product development, opera(cid:415)onal efficiency and disciplined capital alloca(cid:415)on. We remain confident in the long-term opportunity for Hexagon Nutri(cid:415)on and are commi(cid:425)ed to crea(cid:415)ng sustainable value for all our stakeholders”. About Hexagon Nutri(cid:415)on Limited: Hexagon Nutri(cid:415)on Limited is a leading integrated nutri(cid:415)on company engaged in the development, manufacturing and marke(cid:415)ng of nutri(cid:415)onal products across mul(cid:415)ple categories including micronutrient premixes, therapeu(cid:415)c nutri(cid:415)on, clinical nutri(cid:415)on, food for(cid:415)fica(cid:415)on, consumer nutri(cid:415)on and specialised nutri(cid:415)on solu(cid:415)ons. The Company serves customers across India and several interna(cid:415)onal markets through its diversified por(cid:414)olio catering to food manufacturers, pharmaceu(cid:415)cal companies, healthcare ins(cid:415)tu(cid:415)ons and consumers. Hexagon's manufacturing facili(cid:415)es are supported by strong research and development capabili(cid:415)es, enabling the Company to develop innova(cid:415)ve nutri(cid:415)on solu(cid:415)ons aligned with evolving global healthcare and nutri(cid:415)on trends. The Company operates four manufacturing facili(cid:415)es across India and Uzbekistan, with facili(cid:415)es located in Nashik, Maharashtra; Chennai and Thoothukudi, Tamil Nadu; and Tashkent, Uzbekistan. It has a global presence through its subsidiaries and offices across India, South Africa, Uzbekistan and Hong Kong. For more informa(cid:415)on, please contact: Adfactors PR Private Limited (Investor Rela(cid:415)ons) Saloni Nagvekar: saloni.nagvekar@adfactorspr.com / Yashita She(cid:425)y: Yashita.she(cid:425)y@adfactorspr.com